Biotech Movers

Updated April 14, 2026

Stocks with the most signal activity right now: fund position changes, insider purchases, and upcoming catalysts from 20 specialist biotech hedge funds. Ranked by composite activity score.

How the activity score works

What counts as a mover?

Any biotech stock with recent signal activity: new or changed fund positions from the latest 13F filings, insider purchases in the last 30 days, or an upcoming catalyst within 90 days. Stocks are ranked by an activity score that weights these signals.

How often is this updated?

This page refreshes every hour. Fund position data updates quarterly after 13F filing deadlines. Insider signals are ingested daily from SEC EDGAR Form 4 filings. Catalyst dates are refreshed weekly.

What does the activity score mean?

The activity score combines the number of funds with recent position changes, insider buying activity and dollar volume, catalyst proximity, and fund convergence. Higher scores indicate more concurrent signal activity around a stock.

Are exits and trims included?

Yes. Fund exits and trims appear in the table because they are actionable signals. A multi-fund exit from a stock is just as informative as a multi-fund accumulation.

691 active tickers10 with insider buys18 catalysts in 30d

Ticker	Fund Signal	Funds↕	Insider Buys↕	Next Catalyst↕	Score?↓
WVE Wave Life Sciences Ltd.	Added RA Capital Management, RTW Investments	2	4 $54.6M	74d Ph2	140
LENZ LENZ Therapeutics, Inc.	Exited RTW Investments, Deerfield Management	3	3 $366K	—	130
DYN Dyne Therapeutics Inc.	Added Baker Bros. Advisors, RA Capital Management +3	3	1 $34K	—	125
ZBIO Zenas BioPharma, Inc.	Exited Deerfield Management	—	4 $5.5M	77d Ph3	115
MLYS Mineralys Therapeutics, Inc.	Exited Deerfield Management, RTW Investments +1	2	2 $8.8M	—	115
GPCR Structure Therapeutics Inc.	Trimmed Baker Bros. Advisors, BVF Partners +4	6	—	108d Ph2	110
FDMT 4D Molecular Therapeutics, Inc.	Added Baker Bros. Advisors, RA Capital Management +3	5	—	77d Ph2	105
CNTA Centessa Pharmaceuticals plc	Added Baker Bros. Advisors, BVF Partners +2	3	—	16d Ph2	105
TNGX Tango Therapeutics Inc.	Exited Baker Bros. Advisors, Deerfield Management +3	3	—	47d Ph2	100
IDYA IDEAYA Biosciences Inc.	Added Baker Bros. Advisors, BVF Partners +2	5	—	69d Ph2	90
AGIO Agios Pharmaceuticals Inc.	Exited Baker Bros. Advisors, BVF Partners +2	4	—	47d Ph2	85
IRON Disc Medicine Inc.	New BVF Partners, RA Capital Management +2	2	—	169d Ph2	85
SYRE Spyre Therapeutics, Inc.	Exited BVF Partners, RA Capital Management +2	3	—	77d Ph2	80
INSM Insmed Incorporated	Trimmed Baker Bros. Advisors, RA Capital Management +2	3	—	261d Ph3	80
STOK Stoke Therapeutics, Inc.	Trimmed Baker Bros. Advisors, BVF Partners +3	2	—	351d Ph3	80
AKRO Akero Therapeutics Inc.	Exited Baker Bros. Advisors, Deerfield Management +1	5	—	16d Ph3	80
RNA Avidity Biosciences Inc.	Exited Baker Bros. Advisors, Casdin Capital +2	5	—	139d Ph3	80
CMPS COMPASS Pathways plc	Exited Baker Bros. Advisors, BVF Partners +3	1	—	77d Ph3	80
VSTM Verastem, Inc.	Exited Baker Bros. Advisors, BVF Partners +3	2	—	77d Ph2	80
RVMD Revolution Medicines Inc.	Trimmed BVF Partners, Casdin Capital +2	4	—	77d Ph3	80
CGON CG Oncology, Inc.	Exited BVF Partners, RA Capital Management +2	4	—	77d Ph2	80
ITOS iTeos Therapeutics SA	Exited BVF Partners, Baker Bros. Advisors +2	3	—	—	75
CRNX Crinetics Pharmaceuticals Inc.	Added Baker Bros. Advisors, BVF Partners +1	3	—	200d Ph2	75
IONS Ionis Pharmaceuticals Inc.	Added Baker Bros. Advisors, BVF Partners	3	—	16d Ph3	75
KYMR Kymera Therapeutics Inc.	Added Baker Bros. Advisors, Redmile Group +2	2	—	442d Ph2	75
PRAX Praxis Precision Medicines, Inc.	Added Baker Bros. Advisors, RA Capital Management +1	3	—	77d Ph3	75
VERV Verve Therapeutics Inc.	Exited Baker Bros. Advisors, BVF Partners +2	3	—	—	75
XNCR Xencor Inc.	Added BVF Partners, RA Capital Management +2	2	—	232d Ph2	75
RZLT Rezolute, Inc.	Exited BVF Partners, RA Capital Management +1	1	1 $29K	534d Ph3	75
ETNB 89bio Inc.	Exited BVF Partners, RA Capital Management +2	6	—	—	75
RCUS Arcus Biosciences Inc.	New Baker Bros. Advisors, RA Capital Management	1	—	16d Ph2	70
ROIV Roivant Sciences Ltd.	Added Baker Bros. Advisors, BVF Partners +2	2	—	—	70
MDLN Medline Inc.	New RA Capital Management, Deerfield Management +1	—	—	230d Ph2	70
APLS Apellis Pharmaceuticals Inc.	New RTW Investments, Deerfield Management	3	—	442d Ph2	70
AHCO AdaptHealth Corp.	—	1	2 $4.4M	—	70
ABSI Absci Corp	New Baker Bros. Advisors, Deerfield Management	4	—	—	65
ARWR Arrowhead Pharmaceuticals Inc.	Added Baker Bros. Advisors, Deerfield Management +1	2	—	47d Ph3	65
DSGN Design Therapeutics, Inc.	Added Baker Bros. Advisors, RA Capital Management +1	2	—	34d Ph3	65
JBIO Jade Biosciences, Inc.	New Baker Bros. Advisors, RA Capital Management +1	1	—	—	65
TERN Terns Pharmaceuticals Inc.	New Baker Bros. Advisors, Deerfield Management	3	—	—	65
PCVX Vaxcyte Inc.	Exited Baker Bros. Advisors, RA Capital Management +1	4	—	292d Ph3	65
RCKT Rocket Pharmaceuticals Inc.	Exited Baker Bros. Advisors, RA Capital Management +1	2	—	21d Ph2	65
VRNA Verona Pharma plc	Exited Baker Bros. Advisors, RA Capital Management +1	2	—	15d Ph2	65
ARVN Arvinas Inc.	Exited Baker Bros. Advisors, RA Capital Management +2	1	—	595d Ph2	65
COGT Cogent Biosciences Inc.	Exited Baker Bros. Advisors, RA Capital Management +2	2	—	77d Ph2	65
DAWN Day One Biopharmaceuticals Inc.	Exited Baker Bros. Advisors, RA Capital Management +2	2	—	412d Ph2	65
AAVXF Abivax S.A.	Trimmed BVF Partners, RTW Investments	3	—	16d Ph3	65
AXSM Axsome Therapeutics Inc.	Trimmed BVF Partners, RA Capital Management +1	4	—	231d Ph2	65
CELC Celcuity Inc.	Exited BVF Partners, RA Capital Management +2	2	—	77d Ph3	65
EXAS Exact Sciences Corporation	Exited RA Capital Management, Deerfield Management +2	2	—	245d Ph2	65

Showing 50 of 691

Get movers before the market opens

Fund moves, insider buys, and catalyst alerts — delivered free every Monday.

See why WVE is active — and what comes next

AI context on every fund move, insider trade, and catalyst. Full access for 14 days, no credit card required.

Start 14-Day Free Trial

Drill into any signal

Fund Convergence

See which stocks multiple specialist funds are buying at once

Catalyst Calendar

Every PDUFA date, Phase 3 readout, and AdCom in one view

Insider Trading

When executives buy their own stock — the strongest bullish signal

Cash Runway

Which biotechs are running low on cash and face dilution risk

Short Squeeze

High short interest + fund buying + upcoming catalyst = squeeze setup

Signal Rankings

Every signal in one composite score — ranked by conviction

13F Changes

What top biotech funds bought and sold in the latest 13F filing

Want AI context on every signal? Start free trial →